19:53 , Aug 4, 2017 |  BC Week In Review  |  Financial News

Follow-on Roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1 million...
23:20 , Jul 28, 2017 |  BC Extra  |  Financial News

Follow-on roundup: Actinium, Kamada, Tetraphase

Immunotherapy play Actinium Pharmaceuticals Inc. (NYSE-M:ATNM), orphan disease company Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) and infectious disease company Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) each priced follow-on offerings, raising more than $96 million combined. Actinium raised $16.1 million...
23:31 , Jun 22, 2017 |  BC Week In Review  |  Clinical News

Kamada withdraws MAA for inhaled ATT

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said it withdrew its MAA for inhaled alpha-1 antitrypsin (AAT-IH, aerosolized alpha-1 antitrypsin) to treat alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency following discussions with EMA. According to the company, EMA...
23:21 , Jun 22, 2017 |  BC Extra  |  Company News

Kamada withdraws MAA for inhaled AAT

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) said that following discussions with EMA, it withdrew its MAA for inhaled alpha-1 antitrypsin (AAT; A1AT; SERPINA1) to treat AAT deficiency. The company said it does not believe existing data...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Inhaled alpha-1 antitrypsin: Phase II data

Top-line data from a double-blind, U.S. Phase II trial in 36 patients with AAT deficiency showed that once-daily 80 and 160 mg doses of inhaled AAT for 12 weeks each met the co-primary endpoints of...
07:00 , Aug 30, 2016 |  BC Extra  |  Clinical News

Kamada's inhaled AAT meets in U.S. Phase II

Kamada Ltd. (Tel Aviv:KMDA; NASDAQ:KMDA) advanced $0.36 to $4.89 on NASDAQ on Tuesday after its inhaled alpha-1 antitrypsin ( AAT; A1AT; SERPINA1) met the primary endpoint in a 36-patient U.S. Phase II study to treat...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Clinical News

Inhaled alpha-1 antitrypsin regulatory update

EMA accepted for review an MAA from Kamada for inhaled alpha-1 antitrypsin (AAT) to treat AAT deficiency. The MAA is based on a Phase II/III trial in 168 patients in which twice-daily inhaled AAT missed...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

Aerosolized Alpha-1 antitrypsin: Completed Phase II enrollment

Kamada completed enrollment of 36 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 80 or 160 mg inhaled AAT twice daily for 12 weeks. The product uses the eFlow Nebulizer System from Pari....
07:00 , Sep 8, 2014 |  BC Week In Review  |  Clinical News

Aerosolized Alpha-1 antitrypsin: Phase II/III final data

Final data from a double-blind, European and Canadian Phase II/III trial in 168 patients with AAT deficiency showed that twice-daily 160 mg inhaled AAT for 50 weeks missed the secondary endpoints of reducing the time...
07:00 , May 19, 2014 |  BC Week In Review  |  Clinical News

Aerosolized Alpha-1 antitrypsin: Phase II/III data

Top-line data from a double-blind, European and Canadian Phase II/III trial in 168 patients with AAT deficiency showed that twice-daily 160 mg inhaled AAT missed the primary endpoint of improving time to first moderate or...